- Home
- SCNX vs IGC Comparison
SCNX vs IGC Comparison
Compare SCNX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- IGC
- Stock Information
- Founded
- SCNX 2010
- IGC 2005
- Country
- SCNX United States
- IGC United States
- Employees
- SCNX N/A
- IGC N/A
- Industry
- SCNX Other Pharmaceuticals
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- IGC Health Care
- Exchange
- SCNX Nasdaq
- IGC Nasdaq
- Market Cap
- SCNX 21.2M
- IGC 39.8M
- IPO Year
- SCNX 2020
- IGC N/A
- Fundamental
- Price
- SCNX $0.90
- IGC $0.42
- Analyst Decision
- SCNX
- IGC Strong Buy
- Analyst Count
- SCNX 0
- IGC 2
- Target Price
- SCNX N/A
- IGC $4.00
- AVG Volume (30 Days)
- SCNX 475.0K
- IGC 1.3M
- Earning Date
- SCNX 11-05-2025
- IGC 11-11-2025
- Dividend Yield
- SCNX N/A
- IGC N/A
- EPS Growth
- SCNX N/A
- IGC N/A
- EPS
- SCNX N/A
- IGC N/A
- Revenue
- SCNX $128,202.00
- IGC $1,327,000.00
- Revenue This Year
- SCNX N/A
- IGC $15.26
- Revenue Next Year
- SCNX N/A
- IGC $3.41
- P/E Ratio
- SCNX N/A
- IGC N/A
- Revenue Growth
- SCNX N/A
- IGC 24.95
- 52 Week Low
- SCNX $0.69
- IGC $0.25
- 52 Week High
- SCNX $9.55
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- SCNX 34.33
- IGC 53.04
- Support Level
- SCNX $0.86
- IGC $0.38
- Resistance Level
- SCNX $1.16
- IGC $0.47
- Average True Range (ATR)
- SCNX 0.08
- IGC 0.03
- MACD
- SCNX 0.02
- IGC -0.00
- Stochastic Oscillator
- SCNX 20.48
- IGC 37.44
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.